BioProtect Balloon Implant System – Enabling Safe Prostate Radiation Treatment even at extreme dosagebroad
ProSpace · Horizon Europe grant · 2023-10-01–2025-09-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2023-ACCELERATOROPEN-01. CORDIS record →
Objective
Prostate is the 2nd leading cancer in men in the world, with more than 1.4 million men diagnosed every year globally. ~50% of men will be treated with radiation treatment. Radiation is a highly effective treatment; however, it has significant complications, mainly injuring the rectal tissue, approximate to the prostate treatment area. Up to 35% of the patients will experience rectal toxicity side effects such as bleeding, urinary, bowl and erectile dysfunction, damaging severely patient’s quality of life. There is a growing need for a solution that protects the rectum from the radiation field. Our soluton ‘ProSpace’ is a biodegradable medical grade copolymer (70:30 Poly L-Lactide-co-ε-Caprolactone) balloon spacer deployed in the prostate-rectum interspace. It creates a 1.8cm, symmetric distance between the prostate & rectum, allowing physicians to radiate prostate tumours & sparing healthy rectal tissue.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| BIOPROTECT LTD | IL | coordinator | €2,500,000 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.